NONOP2

Across TCGA pan-cancer cohorts, NONOP2 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated NONOP2 data layer.

The strongest signal is observed in brain lower grade glioma (LGG), where higher NONOP2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated NONOP2 expression acts as an unfavorable survival marker, although some lineages such as READ and SKCM show a favorable association.

LGG, MESO, and READ are the cancer types where NONOP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.665	0.810	<.001	54	view →
MESO	OS	Tertile	All	0.291	0.522	.012	34	view →
READ	OS	Quartile	II,III,IV	0.906	0.314	.001	29	view →
SKCM	OS	Quartile	III,IV	0.654	0.312	<.001	27	view →
COAD	DFS	Median	All	0.374	0.606	.002	22	view →
KIRC	DFS	Tertile	IV	0.205	0.520	.009	20	view →
UCEC	OS	Tertile	All	0.901	0.953	.014	20	view →
CHOL	DFS	Median	All	0.663	0.127	.002	18	view →
ACC	DFS	Tertile	III,IV	0.687	0.348	.006	11	view →
UVM	DFS	Quartile	III,IV	0.216	0.832	.004	10	view →
TGCT	DFS	Tertile	All	0.912	0.714	.011	8	view →
THCA	OS	Quartile	II,III,IV	0.817	1.000	.020	7	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

NONOP2–LGG (DFS)

Open the LGG breakdown →